Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal
hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately …

Summary LAG-3, TIM-3, and TIGIT comprise the next generation of immune checkpoint
receptors being harnessed in the clinic. Although initially studied for their roles in restraining …

T cell immunoglobulin and mucin domain 3 (TIM-3) expression on malignant cells has been
reported in some leukemias. In myelodysplastic syndrome (MDS), increased TIM-3 …

CD8+ T cells play a central role in antitumour immunity, which often exhibit 'exhaustion'in the
setting of malignancy and chronic viral infection due to T cell immunoglobulin and mucin …

Myelodysplastic syndromes (MDS) comprise hematological disorders that originate from the
neoplastic transformation of hematopoietic stem cells (HSCs). However, discrimination …

Abstract T-cell immunoglobulin mucin-3 (Tim-3), an inhibitory immune checkpoint receptor,
is highly expressed on acute myeloid leukemia cells and its ligand galectin-9 is reported to …

Immune checkpoint inhibitors (ICI) have yielded mixed but largely underwhelming results in
clinical trials in patients with acute myeloid leukemia and myelodysplastic syndromes to …

In the last twenty years, we have witnessed a paradigm shift in the treatment and prognosis
of acute myeloid leukemia (AML), thanks to the introduction of new efficient drugs or …

The Philadelphia chromosome-negative (Ph−) myeloproliferative neoplasms (MPNs), which
include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) …

In work spanning several decades, extensive studies have focused on the properties of
malignant stem cells that drive the pathogenesis of acute myeloid leukemia (AML). However …